Kremers Urban Pharmaceuticals Inc., a specialty generic drug manufacturer and wholly owned subsidiary of Lannett Company, Inc., is a pioneer in developing generic versions of pharmaceutical products that are either difficult to formulate or utilize specialized delivery technologies. The Company is moving to the forefront of delivering the tough solutions necessary to get complex products into the market.

The newest product in the Kremers Urban portfolio is Temozolomide Capsules. The Kremers Urban portfolio also provides several difficult-to-manufacture and extended-release products that require complex drug development technology and manufacturing process including: Atorvastatin Calcium Tablets, Hydrocodone Polistirex and Chlorpheniramine Polistirex Pennkinetic® Extended-Release Suspension CII (authorized generic for Tussionex® Pennkinetic® Extended-Release Suspension CII), Methylphenidate HCI Extended-Release Capsules CD CII (authorized generic for Metadate CD® CII), Methylphenidate HCl Extended-Release Tablets, USP CII, Pantoprazole Sodium Delayed-Release Tablets USP, Polyethylene Glycol 3350, NF Powder for Oral Solution, Oxybutynin Chloride Extended-Release Tablets USP, Omeprazole Delayed-Release Capsules USP, Nifedipine Extended-Release Tablets USP, Rabeprazole Sodium Delayed-Release Tablet, Tacrolimus Capsules USP, Verapamil Hydrochloride Extended-Release Capsules (PM), and several other generic products. The Company stands behind each of its products, ensuring the highest standards available.

In addition to aggressively pursuing both in-licensing generic drug products and internal research and development, Kremers Urban looks to expand its generic product portfolio by leveraging their biopharmaceutical capabilities. Kremers Urban also seeks strategic alliances in the development of products and drug delivery technologies that would further enhance its capabilities or offerings.

 

METADATE CD, PENNKINETIC and TUSSIONEX are registered trademarks of the UCB Group of companies. Other cited trademarks are the property of their respective owners

Kremers Urban has made a significant investment in an impressive 400,000-square-foot pharmaceutical manufacturing plant in Seymour, Indiana. With its dedicated facilities, comprehensive infrastructure, and technical expertise the company is uniquely structured and positioned to manage high barriers to entry.